|
시장보고서
상품코드
1819687
북미의 약물감시 및 의약품 안전성 소프트웨어 시장 보고서 : 범위, 부문, 역학, 경쟁 분석(2021-2031년)North America Pharmacovigilance and Drug Safety Software Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis |
||||||
북미의 약물감시 및 의약품 안전성 소프트웨어 시장은 2023년 약 1억3만 달러로 평가되었고 2023년부터 2031년까지의 예측 기간 동안 7.8%의 연평균 복합 성장률(CAGR)로 2031년까지 약 1억 8,272만 달러로 성장할 것으로 예측되고 있습니다.
의약품 부작용 증가
의약품 부작용(ADR) 증가는 북미의 약물감시 및 의약품 안전성 소프트웨어 시장의 성장을 가속하는 중요한 요인입니다. 만성 질환의 유병률은 상승 경향이 있으며, 처방되는 약물의 수가 증가하고 있기 때문에 ADR이 발생할 가능성이 높아지고 있습니다. 모든 의약품이 부작용을 일으킬 수 있다는 점을 감안할 때, 의약품이 처방 될 때마다 철저한 위험 혜택 분석을 수행하는 것이 매우 중요합니다. ADR은 특히 치료 요법의 복잡성, 인구 고령화, 여러 만성 질환의 확산으로 현대 건강 관리에 큰 어려움을 겪고 있습니다.
약물감시 소프트웨어는 의료 제공업체 및 제약 회사가 ADR에 대한 데이터를 체계적으로 수집, 분석 및 보고할 수 있도록 하는 데 중요한 역할을 합니다. 이 소프트웨어는 미국 식품의약국의 부작용 보고 시스템(FAERS) 데이터에서도 알 수 있듯이 ADR이 초래하는 과제를 해결하는 데 필수적이며, 2022년에만 125만 건이 넘는 심각한 부작용 사례와 17만 5,000명 이상의 사망 사례가 보고되었습니다.
테오필린과 마크로라이드계 항생제의 상호작용과 비타민 K 섭취량 증가와 같은 특정 약물의 상호작용은 ADR과 관련이 있습니다. ADR의 보고 건수가 증가의 길을 따라가는 가운데, 제약회사, 의료 제공자, 규제기관에 대한 의약품 안전성 감시·보고 프로세스의 강화에 대한 압력이 높아지고 있습니다. 약물감시 및 의약품 안전성 소프트웨어는 부작용의 검출, 평가, 예방을 간소화하여 신속한 대응과 보다 정확한 위험 평가를 촉진합니다. 그 결과, ADR 발생률 증가가 약물감시 및 의약품 안전성 소프트웨어 시장 성장의 주요 촉진요인이 되고 있습니다.
북미 시장 개요
북미의 약물감시 및 의약품 안전성 소프트웨어 시장은 미국, 캐나다, 멕시코로 구분됩니다. 북미는 의약품과 의약품의 안전성에 관한 규제를 신속하게 도입한 지역으로 인식되고 있습니다. 또한 이 지역에서는 의약품 부문의 디지털화가 급속히 진행되고 있습니다. Canada Health Infoway에 따르면, 캐나다 제약 회사는 디지털 건강 서비스의 채택을 늘리고 있으며, 이는 앞으로 수년간 약물감시 및 의약품 안전성 소프트웨어 수요를 촉진할 것으로 예측됩니다. 제약 업계에서의 디지털화의 진전은 의약품의 효과적인 모니터링의 필요성을 높여 약물감시 솔루션 수요를 증가시킬 것으로 예측됩니다.
보고되는 부작용의 양이 증가함에 따라, 약물감시 및 의약품 안전 전문가들은 이 데이터를 정확하고 효율적으로 평가하는 데 더 큰 과제에 직면해 있습니다. 부작용 데이터의 정확하고 체계적인 분석을 보장하면서 이러한 전문가의 작업 부담을 줄이기 위해서는 첨단 기술 도입이 필수적입니다.
시장 세분화 분석
북미의 약물감시 및 의약품 안전성 소프트웨어 시장은 제공 제품, 배포, 기업 규모, 형태, 기능, 최종 사용자, 국가 등 다양한 요인에 따라 분류할 수 있습니다.
1. 제공 제품 : 시장은 소프트웨어 및 서비스로 나뉘어 2023년에는 소프트웨어 분야가 큰 점유율을 차지했습니다.
2. 배포 : 시장은 클라우드 기반과 On-Premise 솔루션으로 구분되었으며, 2023년에는 클라우드 솔루션이 시장 점유율을 독점했습니다.
3. 기업 규모 : 시장은 대기업과 중소기업으로 분류되었으며, 2023년에는 대기업이 큰 점유율을 차지했습니다.
4. 형태 : 소프트웨어는 표준 형태와 주문을 받아서 만들어진 형태를 가지고 있고 시장에서는 표준 형태가 대중적입니다.
5. 기능성 : 시장은 신호 및 위험 관리, 문제 추적, 사례 관리, 임상 안전 관리, 품질 및 규정 준수, 건강 관리 분석 등 다양한 기능을 포함하고 있으며, 2023년에는 신호 및 위험 관리가 가장 큰 부문이 되었습니다.
6. 최종 사용자 : 주요 최종 사용자는 제약 및 생명 공학 회사, 의약품 개발 업무 수탁 기관, 비즈니스 프로세스 아웃소싱 회사 등을 포함하며 제약 및 생명 공학 기업이 시장 점유율을 이끌고 있습니다.
7. 국가별 : 시장은 미국, 캐나다, 멕시코로 구분되었으며, 2023년에는 미국이 시장을 독점했습니다.
시장의 주요 기업
북미의 Pharma Cobigilance 및 제약 안전 소프트웨어 시장에서 Veeva Systems Inc., IQVIA Holdings Inc., AB Cube SAS, ArisGlobal LLC, Oracle Corp., Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Corp., GenLacme Holdings, Parexel International Corp, Qinecsa Solutions, Clinevo Technologies 등 여러 유력 기업들이 활약하고 있습니다. 이러한 기업들은 이 지역에서의 의약품 안전성과 약물감시의 실천을 강화하는 혁신적인 솔루션 개발의 최전선에 있습니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
- 시장의 매력
제3장 조사 방법
- 2차 조사
- 1차 조사
- 가설의 책정
- 거시경제 요인분석
- 기초 수치의 개발
- 데이터의 삼각측량
- 국가 수준 데이터
- 전제조건과 제한
제4장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 상황
- 소프트웨어/서비스 제공업체
- 시스템 통합자
- 규제기관
- 최종 사용자
- 밸류체인의 공급업체 일람
제5장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 의약품 부작용 증가
- 약물감시의 세계화
- 의약품 개발비의 급증
- 시장 성장 억제요인
- 높은 설치 비용과 유지 보수 비용
- 시장 기회
- AI, ML, NLP와 소프트웨어의 통합
- 향후의 동향
- 클라우드 기반의 약물감시 및 의약품 안전성 소프트웨어
- 성장 촉진요인과 억제요인의 영향
제6장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석
- 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 수익, 2021년-2031년
- 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 예측 분석
제7장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 제공 제품별
- 소프트웨어
- 서비스
제8장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 전개별
- 클라우드
- On-Premise
제9장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 기업 규모별
- 대기업
- 중소기업
제10장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 형태별
- 표준형
- 커스터마이즈
제11장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 기능별
- 시그널과 리스크 관리
- 문제 추적 및 부작용 추적
- 사례 관리
- 임상 안전성 관리 및 임상시험 안전성
- 품질 및 규정 준수
- 메디컬 라이팅
- 감사 지원 및 교육 규정 준수
- 헬스케어 분석
- 기타
제12장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 : 최종 사용자별
- 제약회사 및 바이오테크놀러지 기업
- 계약 연구 기관
- 비즈니스 프로세스 아웃소싱(BPO) 기업
- 기타
제13장 북미의 약물감시 및 의약품 안전성 소프트웨어 시장 : 국가별 분석
- 북미
- 미국
- 캐나다
- 멕시코
제14장 경쟁 구도
- 히트 맵 분석 : 주요 기업별
- 기업의 포지셔닝과 집중도
제15장 업계 정세
- 시장 이니셔티브
- 파트너십 및 협업
제16장 기업 프로파일
- ArisGlobal LLC
- Max Application
- Oracle Corp
- Veeva Systems Inc
- IQVIA Holdings Inc
- ICON Plc
- Cognizant Technology Solutions Corp
- Accenture Plc
- Syneos Health Inc
- Genpact Ltd.
- AB Cube SAS
- Laboratory Corp of America Holdings
- Parexel International Corp
- Qinecsa Solutions
- Clinevo Technologies
제17장 부록
SHW 25.10.01The North American pharmacovigilance and drug safety software market was valued at approximately $100.03 million in 2023 and is projected to grow to about $182.72 million by 2031, reflecting a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2023 to 2031.
Increasing Incidence of Adverse Drug Reactions
The rise in adverse drug reactions (ADRs) is a significant factor driving the growth of the pharmacovigilance and drug safety software market in North America. The prevalence of chronic diseases is on the rise, leading to an increase in the number of medications prescribed, which in turn raises the potential for ADRs. Given that all medications can cause adverse reactions, conducting a thorough risk-benefit analysis is crucial whenever a drug is prescribed. ADRs pose a considerable challenge in contemporary healthcare, especially with the increasing complexity of treatment regimens, an aging population, and the prevalence of multiple chronic conditions.
Pharmacovigilance software plays a vital role in enabling healthcare providers and pharmaceutical companies to systematically collect, analyze, and report data related to ADRs. This software is essential for addressing the challenges posed by ADRs, as evidenced by the data from the US Food and Drug Administration's Adverse Event Reporting System (FAERS), which reported over 1.25 million severe adverse cases and more than 175,000 deaths in 2022 alone.
The interaction of certain medications, such as theophylline with macrolide antibiotics and increased vitamin K consumption, has been linked to ADRs. As the number of reported ADRs continues to rise, there is increasing pressure on pharmaceutical companies, healthcare providers, and regulatory bodies to enhance drug safety monitoring and reporting processes. Pharmacovigilance and drug safety software streamline the detection, assessment, and prevention of adverse effects, facilitating quicker response times and more accurate risk assessments. Consequently, the growing incidence of ADRs is a key driver of market growth in pharmacovigilance and drug safety software.
Overview of the North American Market
The North American pharmacovigilance and drug safety software market is segmented into the United States, Canada, and Mexico. North America is recognized as an early adopter of regulations concerning pharmaceutical and drug safety. Additionally, the region is witnessing a surge in digitization within the pharmaceutical sector. According to Canada Health Infoway, pharmaceutical companies in Canada are increasingly adopting digital health services, which is expected to drive demand for pharmacovigilance and drug safety software in the coming years. The growing digitization in the pharmaceutical industry is anticipated to enhance the need for effective monitoring of pharmaceutical drugs, thereby increasing the demand for pharmacovigilance solutions.
As the volume of reported adverse events rises, pharmacovigilance and drug safety professionals face greater challenges in accurately and efficiently evaluating this data. The implementation of advanced technologies is crucial to alleviate the workload of these professionals while ensuring precise and systematic analysis of adverse event data.
Market Segmentation Analysis
The North American pharmacovigilance and drug safety software market can be categorized based on various factors, including offering, deployment, enterprise size, form, functionality, end user, and country.
1. Offering: The market is divided into software and services, with the software segment holding a larger share in 2023.
2. Deployment: The market is further segmented into cloud-based and on-premises solutions, with cloud solutions dominating the market share in 2023.
3. Enterprise Size: The market is categorized into large enterprises and small to medium-sized enterprises (SMEs), with large enterprises holding a significant share in 2023.
4. Form: The software is available in standard and customized forms, with the standard form being more prevalent in the market.
5. Functionality: The market includes various functionalities such as signal and risk management, issue tracking, case management, clinical safety management, quality and compliance, and healthcare analytics, with signal and risk management being the largest segment in 2023.
6. End User: The primary end users include pharmaceutical and biotechnology companies, contract research organizations, and business process outsourcing firms, with pharmaceutical and biotechnology companies leading the market share.
7. Country: The market is segmented into the US, Canada, and Mexico, with the US dominating the market in 2023.
Key Players in the Market
Several prominent companies are active in the North American pharmacovigilance and drug safety software market, including Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions to enhance drug safety and pharmacovigilance practices in the region.
Table Of Contents
1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
- 2.2 Market Attractiveness
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:
- 3.3 Assumptions and Limitations
4. North America Pharmacovigilance and Drug Safety Software Market Landscape
- 4.1 Overview
- 4.1.1 Software/Service Providers:
- 4.1.2 System Integrators:
- 4.1.3 Regulatory Bodies:
- 4.1.4 End-Users:
- 4.2 List of Vendors in the Value Chain
5. North America Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
- 5.1
- 5.1 Market Drivers
- 5.1.1 Rise in Incidences of Adverse Drug Reactions
- 5.1.2 Globalization of Pharmacovigilance
- 5.1.3 Surge in Drug Development Spending
- 5.2 Market Restraints
- 5.2.1 High Installation and Maintenance Costs
- 5.3 Market Opportunities
- 5.3.1 Integration of Software with AI, ML, and NLP
- 5.4 Future Trends
- 5.4.1 Cloud-Based Pharmacovigilance and Drug Safety Software:
- 5.5 Impact of Drivers and Restraints:
6. North America Pharmacovigilance and Drug Safety Software Market - Analysis
- 6.1 North America Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
- 6.2 North America Pharmacovigilance and Drug Safety Software Market Forecast Analysis
7. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Offering
- 7.1 Software
- 7.1.1 Overview
- 7.1.2 Software: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 7.2 Services
- 7.2.1 Overview
- 7.2.2 Services: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment
- 8.1 Cloud
- 8.1.1 Overview
- 8.1.2 Cloud: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 8.2 On Premises
- 8.2.1 Overview
- 8.2.2 On Premises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size
- 9.1 Large Enterprises
- 9.1.1 Overview
- 9.1.2 Large Enterprises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 9.2 SMEs
- 9.2.1 Overview
- 9.2.2 SMEs: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
10. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Form
- 10.1 Standard
- 10.1.1 Overview
- 10.1.2 Standard: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.2 Customized
- 10.2.1 Overview
- 10.2.2 Customized: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality
- 11.1 Signal and Risk Management
- 11.1.1 Overview
- 11.1.2 Signal and Risk Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.2 Issue Tracking and Adverse Event Tracking
- 11.2.1 Overview
- 11.2.2 Issue Tracking and Adverse Event Tracking: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.3 Case Management
- 11.3.1 Overview
- 11.3.2 Case Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.4 Clinical Safety Management and Clinical Trial Safety
- 11.4.1 Overview
- 11.4.2 Clinical Safety Management and Clinical Trial Safety: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.5 Quality and Compliance
- 11.5.1 Overview
- 11.5.2 Quality and Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.6 Medical Writing
- 11.6.1 Overview
- 11.6.2 Medical Writing: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.7 Audit Support and Training Compliance
- 11.7.1 Overview
- 11.7.2 Audit Support and Training Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.8 Healthcare Analytics
- 11.8.1 Overview
- 11.8.2 Healthcare Analytics: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 11.9 Others
- 11.9.1 Overview
- 11.9.2 Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
12. North America Pharmacovigilance and Drug Safety Software Market Analysis - by End User
- 12.1 Pharmaceutical and Biotechnology Companies
- 12.1.1 Overview
- 12.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 12.2 Contract Research Organizations
- 12.2.1 Overview
- 12.2.2 Contract Research Organizations: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 12.3 Business Process Outsourcing (BPO) Firms
- 12.3.1 Overview
- 12.3.2 Business Process Outsourcing (BPO) Firms: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 12.4 Others
- 12.4.1 Overview
- 12.4.2 Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
13. North America Pharmacovigilance and Drug Safety Software Market - Country Analysis
- 13.1 North America
- 13.1.1 North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
- 13.1.1.1 North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
- 13.1.1.2 United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 13.1.1.2.1 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
- 13.1.1.2.1 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
- 13.1.1.2.2 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
- 13.1.1.2.3 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
- 13.1.1.2.4 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
- 13.1.1.2.5 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by End User
- 13.1.1.3 Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 13.1.1.3.1 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
- 13.1.1.3.2 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
- 13.1.1.3.3 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
- 13.1.1.3.4 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
- 13.1.1.3.5 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
- 13.1.1.3.6 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by End User
- 13.1.1.4 Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 13.1.1.4.1 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
- 13.1.1.4.2 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
- 13.1.1.4.3 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
- 13.1.1.4.4 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
- 13.1.1.4.5 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
- 13.1.1.4.6 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by End User
- 13.1.1 North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
14. Competitive Landscape
- 14.1 Heat Map Analysis by Key Players
- 14.2 Company Positioning and Concentration
15. Industry Landscape
- 15.1 Overview
- 15.2 Market Initiative
- 15.3 Partnerships and Collaborations
16. Company Profiles
- 16.1 ArisGlobal LLC
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
- 16.2 Max Application
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
- 16.3 Oracle Corp
- 16.3.1 Key Facts
- 16.3.1 Business Description
- 16.3.2 Products and Services
- 16.3.3 Financial Overview
- 16.3.4 SWOT Analysis
- 16.3.5 Key Developments
- 16.4 Veeva Systems Inc
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
- 16.5 IQVIA Holdings Inc
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
- 16.6 ICON Plc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
- 16.7 Cognizant Technology Solutions Corp
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
- 16.8 Accenture Plc
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
- 16.9 Syneos Health Inc
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
- 16.10 Genpact Ltd.
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments
- 16.11 AB Cube S.A.S.
- 16.11.1 Key Facts
- 16.11.2 Business Description
- 16.11.3 Products and Services
- 16.11.4 Financial Overview
- 16.11.5 SWOT Analysis
- 16.11.6 Key Developments
- 16.12 Laboratory Corp of America Holdings
- 16.12.1 Key Facts
- 16.12.2 Business Description
- 16.12.3 Products and Services
- 16.12.4 Financial Overview
- 16.12.5 SWOT Analysis
- 16.12.6 Key Developments
- 16.13 Parexel International Corp
- 16.13.1 Key Facts
- 16.13.2 Business Description
- 16.13.3 Products and Services
- 16.13.4 Financial Overview
- 16.13.5 SWOT Analysis
- 16.13.6 Key Developments
- 16.14 Qinecsa Solutions
- 16.14.1 Key Facts
- 16.14.2 Business Description
- 16.14.3 Products and Services
- 16.14.4 Financial Overview
- 16.14.5 SWOT Analysis
- 16.14.6 Key Developments
- 16.15 Clinevo Technologies
- 16.15.1 Key Facts
- 16.15.2 Business Description
- 16.15.3 Products and Services
- 16.15.4 Financial Overview
- 16.15.5 SWOT Analysis
- 16.15.6 Key Developments
17. Appendix
- 17.1 About Us
- 17.2 List of Abbreviations
